Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 18Lymphoma, Large B-Cell, Diffuse 16Leukemia, Myeloid, Acute 16Hodgkin Disease 16Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lung Neoplasms 12Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Lymphoma, B-Cell 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 6Recurrence 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Congenital Abnormalities 4Waldenstrom Macroglobulinemia 3Plasmablastic Lymphoma 3Ovarian Neoplasms 3Lymphoma, Primary Effusion 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Etoposide × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡